Association of Circulating Cell‐Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1238 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2025. Verfasst von Chao-Hui Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: DNA, Mitochondrial, Hearing Loss, Sensorineural, Hearing Loss, Sudden, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the association of circulating cell‐free mitochondrial DNA (ccf‐mtDNA) levels with the severity and treatment outcomes of sudden sensorineural hearing loss (SSNHL). Study Design Observational prospective study.
Setting
Tertiary academic medical center.
Methods
Plasma samples were collected from patients diagnosed with SSNHL in the morning before steroid treatment, as well as from healthy controls. A quantitative polymerase chain reaction was used to measure ccf‐mtDNA levels, expressed as log copy numbers per milliliter. Treatment outcomes were evaluated using hearing gain, percentage of recovery, and Siegel's criteria.
Results
The study included 80 subjects, including 50 patients and 30 healthy controls. The mean (SD) plasma ccf‐mtDNA level was 8.1 (0.35), which was significantly higher than 7.78 (0.65) controls (95% CI: 0.097‐0.542). Patients with good recovery exhibited significantly higher pretreatment ccf‐mtDNA levels compared to those with poor recovery (mean [SD] score: 8.29 [0.34] vs 8.02 [0.33]; 95% CI: 0.04‐0.48). Ccf‐mtDNA levels were positively associated with hearing gain ( r = 0.486, 95% CI: 0.227‐0.663) and percentage of recovery ( r = 0.361, 95% CI: 0.103‐0.574). Multivariate analyses revealed that less than 7 days from onset of hearing loss to treatment (odds ratio [OR]: 7.389, 95% CI: 1.324‐41.239) and higher ccf‐mtDNA levels (OR: 24.634, 95% CI: 1.878‐323.163) were independent predictors for good recovery.
Conclusion
Plasma ccf‐mtDNA levels were elevated in patients with SSNHL and were significantly associated with better treatment outcomes following steroid therapy. These findings suggest that ccf‐mtDNA levels may serve as a predictive biomarker for SSNHL treatment outcomes, paving the way for personalized therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.
- School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
- Department of Otolaryngology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
- Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Zitieren
APA
Yang, C. H., Yang, M. Y., Lin, W. C., Hwang, C. F., Lin, Y. T., Wu, C. N., Chen, I. Y., & Tsai, M. H. (2025). Association of Circulating Cell‐Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1238
Vancouver
Yang CH, Yang MY, Lin WC, Hwang CF, Lin YT, Wu CN, et al. Association of Circulating Cell‐Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1238
BibTeX
@article{Yang2025,
author = {Yang, Chao-Hui and Yang, Ming-Yu and Lin, Wei-Che and Hwang, Chung-Feng and Lin, Yu-Tsai and Wu, Ching-Nung and Chen, I-Ya and Tsai, Ming-Hsien},
title = {Association of Circulating Cell‐Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1238}
}
EUVIMED